

| 年度 | 審査月 | 核酸アナログ製剤治療 | | | | | | | | | | | | | | | 総計 | | | | | | | | |
|-----|-----|------------|-----|-----|-----|----|-----|----|-----|-----|----|---------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|-----|-----|
| | | 新規 | | | | | 更新 | | | | | 核酸アナログ計 | | | | | 総計 | | | | | | | | |
| | | 申請 | 審査 | 保留 | 不承認 | 交付 | 申請 | 審査 | 保留 | 不承認 | 交付 | 申請 | 審査 | 保留 | 不承認 | 交付 | 申請 | 審査 | 保留 | 不承認 | 交付 | | | | |
| H20 | 4月 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | | |
| | 5月 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 41 | 41 | 5 | 1 | 35 | | | | |
| | 6月 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 120 | 123 | 15 | 1 | 107 | | | | |
| | 7月 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 60 | 75 | 7 | 0 | 68 | | | | |
| | 8月 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 36 | 39 | 2 | 0 | 37 | | | | |
| | 9月 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 18 | 21 | 4 | 0 | 17 | | | | |
| | 10月 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 28 | 32 | 10 | 0 | 22 | | | | |
| | 11月 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 30 | 39 | 3 | 0 | 36 | | | | |
| | 12月 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 22 | 24 | 5 | 0 | 19 | | | | |
| | 1月 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 19 | 24 | 2 | 0 | 22 | | | | |
| | 2月 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 23 | 25 | 0 | 0 | 25 | | | | |
| | 3月 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 14 | 1 | 0 | 13 | | | | |
| | 計 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 46 | 411 | 457 | 54 | 2 | 401 | | | | |
| H21 | 4月 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 25 | 28 | 0 | 0 | 26 | | | | | |
| | 5月 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18 | 18 | 2 | 0 | 16 | | | | | |
| | 6月 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 26 | 28 | 1 | 0 | 27 | | | | | |
| | 7月 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 21 | 22 | 2 | 0 | 20 | | | | | |
| | 8月 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 17 | 19 | 1 | 0 | 18 | | | | | |
| | 9月 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 14 | 15 | 1 | 0 | 14 | | | | | |
| | 10月 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 17 | 18 | 3 | 0 | 15 | | | | | |
| | 11月 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 23 | 26 | 1 | 0 | 25 | | | | | |
| | 12月 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 19 | 20 | 2 | 0 | 18 | | | | | |
| | 1月 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 15 | 17 | 0 | 0 | 17 | | | | | |
| | 2月 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 21 | 1 | 0 | 20 | | | | | |
| | 3月 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 11 | 12 | 1 | 0 | 11 | | | | | |
| | 計 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 227 | 242 | 15 | 0 | 227 | | | | | |
| H22 | 4月 | 0 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 24 | 25 | 5 | 0 | 20 | | | | | |
| | 5月 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 10 | 13 | 1 | 0 | 12 | | | | |
| | 6月 | 2 | 48 | 50 | 1 | 0 | 49 | 0 | 0 | 0 | 0 | 0 | 2 | 48 | 50 | 1 | 0 | 49 | 3 | 80 | 83 | 8 | 0 | 75 | |
| | 7月 | 0 | 156 | 156 | 0 | 0 | 156 | 0 | 0 | 0 | 0 | 0 | 0 | 156 | 156 | 0 | 0 | 156 | 7 | 183 | 190 | 2 | 0 | 188 | |
| | 8月 | 0 | 14 | 14 | 0 | 0 | 14 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 14 | 0 | 0 | 14 | 2 | 31 | 33 | 5 | 0 | 28 | |
| | 9月 | 0 | 12 | 12 | 1 | 0 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 12 | 1 | 0 | 11 | 5 | 29 | 34 | 3 | 0 | 31 | |
| | 10月 | 1 | 14 | 15 | 1 | 0 | 14 | 0 | 0 | 0 | 0 | 0 | 1 | 14 | 15 | 1 | 0 | 14 | 3 | 33 | 36 | 5 | 0 | 31 | |
| | 11月 | 1 | 9 | 10 | 0 | 0 | 10 | 0 | 0 | 0 | 0 | 0 | 1 | 9 | 10 | 0 | 0 | 10 | 5 | 21 | 26 | 2 | 0 | 24 | |
| | 12月 | 0 | 6 | 6 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 | 0 | 0 | 6 | 2 | 28 | 30 | 0 | 0 | 30 | |
| | 1月 | 0 | 3 | 3 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 0 | 0 | 3 | 0 | 25 | 25 | 1 | 0 | 24 | |
| | 2月 | 0 | 5 | 5 | 1 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 5 | 1 | 0 | 4 | 1 | 26 | 27 | 3 | 0 | 24 | |
| | 3月 | 1 | 5 | 6 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 6 | 0 | 0 | 6 | 3 | 8 | 11 | 2 | 0 | 9 | |
| | 計 | 5 | 274 | 279 | 6 | 0 | 273 | 0 | 0 | 0 | 0 | 0 | 5 | 274 | 279 | 6 | 0 | 273 | 35 | 498 | 533 | 37 | 0 | 496 | |
| H23 | 4月 | 0 | 3 | 3 | 0 | 0 | 3 | 0 | 15 | 15 | 0 | 0 | 15 | 0 | 18 | 18 | 0 | 0 | 18 | 1 | 38 | 39 | 2 | 0 | 37 |
| | 5月 | 0 | 11 | 11 | 1 | 0 | 10 | 0 | 4 | 4 | 1 | 0 | 3 | 0 | 15 | 15 | 2 | 0 | 13 | 2 | 24 | 26 | 4 | 0 | 22 |
| | 6月 | 1 | 4 | 5 | 0 | 0 | 5 | 1 | 25 | 26 | 0 | 0 | 26 | 2 | 29 | 31 | 0 | 0 | 31 | 4 | 50 | 54 | 2 | 0 | 52 |
| | 7月 | 0 | 8 | 8 | 0 | 0 | 8 | 0 | 6 | 6 | 0 | 0 | 6 | 0 | 14 | 14 | 0 | 0 | 14 | 2 | 25 | 27 | 2 | 0 | 25 |
| | 8月 | 0 | 2 | 2 | 0 | 0 | 2 | 0 | 12 | 12 | 0 | 0 | 12 | 0 | 14 | 14 | 0 | 0 | 14 | 2 | 26 | 28 | 1 | 0 | 27 |
| | 9月 | 0 | 9 | 9 | 0 | 0 | 9 | 0 | 7 | 7 | 0 | 0 | 7 | 0 | 16 | 16 | 0 | 0 | 16 | 1 | 24 | 25 | 0 | 0 | 25 |
| | 10月 | 0 | 3 | 3 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 0 | 0 | 3 | 0 | 14 | 14 | 0 | 0 | 14 | |
| | 11月 | 0 | 2 | 2 | 0 | 0 | 2 | 0 | 5 | 5 | 0 | 0 | 5 | 0 | 7 | 7 | 0 | 0 | 7 | 0 | 16 | 16 | 1 | 0 | 15 |
| | 12月 | 0 | 7 | 7 | 0 | 0 | 7 | 0 | 4 | 4 | 0 | 0 | 4 | 0 | 11 | 11 | 0 | 0 | 11 | 1 | 24 | 25 | 1 | 1 | 23 |
| | 1月 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 10 | 10 | 0 | 0 | 10 | 0 | 11 | 11 | 0 | 0 | 11 | 1 | 23 | 24 | 2 | 0 | 22 |
| | 2月 | 0 | 7 | 7 | 0 | 0 | 7 | 0 | 98 | 98 | 0 | 0 | 98 | 0 | 105 | 105 | 0 | 0 | 105 | 2 | 127 | 129 | 0 | 0 | 129 |
| | 3月 | 0 | 8 | 8 | 0 | 0 | 8 | 0 | 58 | 58 | 0 | 0 | 58 | 0 | 66 | 66 | 0 | 0 | 66 | 0 | 79 | 79 | 0 | 0 | 79 |
| | 計 | 1 | 65 | 66 | 1 | 0 | 65 | 1 | 244 | 245 | 1 | 0 | 244 | 2 | 309 | 311 | 2 | 0 | 309 | 16 | 470 | 486 | 15 | 1 | 470 |
| H24 | 4月 | 0 | 3 | 3 | 0 | 0 | 3 | 0 | 32 | 32 | 4 | 0 | 28 | 0 | 35 | 35 | 4 | 0 | 31 | 0 | 59 | 59 | 4 | 0 | 55 |
| | 5月 | 0 | 4 | 4 | 0 | 0 | 4 | 4 | 16 | 20 | 2 | 0 | 18 | 4 | 20 | 24 | 2 | 0 | 22 | 4 | 34 | 38 | 2 | 0 | 36 |
| | 6月 | 0 | 4 | 4 | 0 | 0 | 4 | 2 | 19 | 21 | 0 | 0 | 21 | 2 | 23 | 25 | 0 | 0 | 25 | 2 | 31 | 33 | 1 | 0 | 32 |
| | 7月 | 0 | 2 | 2 | 0 | 0 | 2 | 0 | 15 | 15 | 0 | 0 | 15 | 0 | 17 | 17 | 0 | 0 | 17 | 1 | 31 | 32 | 0 | 0 | 32 |
| | 8月 | 0 | 9 | 9 | 0 | 0 | 9 | 0 | 9 | 9 | 0 | 0 | 9 | 0 | 18 | 18 | 0 | 0 | 18 | 0 | 29 | 29 | 0 | 0 | 29 |
| | 9月 | 0 | 6 | 6 | 0 | 0 | 6 | 0 | 11 | 11 | 1 | 0 | 10 | 0 | 17 | 17 | 1 | 0 | 16 | 0 | 31 | 31 | 1 | 0 | 30 |
| | 10月 | 0 | 7 | 7 | 1 | 0 | 6 | 1 | 7 | 8 | 1 | 0 | 7 | 1 | 14 | 15 | 2 | 0 | 13 | 1 | 31 | 32 | 4 | 0 | 28 |
| | 11月 | 1 | 4 | 5 | 0 | 0 | 5 | 1 | 10 | 11 | 0 | 0 | 11 | 2 | 14 | 16 | 0 | 0 | 16 | 4 | 27 | 31 | 0 | 0 | 31 |
| | 12月 | 0 | 3 | 3 | 0 | 1 | 2 | 0 | 7 | 7 | 0 | 0 | 7 | 0 | 10 | 10 | 0 | 1 | 9 | 0 | 12 | 12 | 0 | 1 | 11 |
| | 1月 | 0 | 4 | 4 | 1 | 0 | 3 | 0 | 28 | 28 | 0 | 0 | 28 | 0 | 32 | 32 | 1 | 0 | 31 | 0 | 49 | 49 | 4 | 0 | 45 |
| | 2月 | 1 | 5 | 6 | 1 | 0 | 5 | 0 | 72 | 72 | 0 | 0 | 72 | 1 | 77 | 78 | 1 | 0 | 77 | 4 | 90 | 94 | 1 | 0 | 93 |
| | 3月 | 1 | 6 | 7 | 0 | 0 | 7 | 0 | 75 | 75 | 0 | 0 | 75 | 1 | 81 | 82 | 0 | 0 | 82 | 1 | 85 | 86 | 0 | 0 | 86 |
| | 計 | 3 | 57 | 60 | 3 | 1 | 56 | 8 | 301 | 309 | 8 | 0 | 301 | 11 | 358 | 369 | 11 | 1 | 357 | 17 | 509 | 526 | 17 | 1 | 508 |

| 再掲:新規交付者数 | | | | | | |
|-----------|--------|-----|-----------|---------|--------|-----|
| B型肝炎患者 | | | C型肝炎患者 | | | 総計 |
| IFN | 核酸アナログ | 計 | IFN(単+2剤) | IFN(3剤) | IFNフリー | |
| | | 0 | | | | 0 |
| | | 2 | 33 | | | 33 |
| | | 2 | 105 | | | 107 |
| | | 0 | 68 | | | 68 |
| | | 1 | 36 | | | 36 |
| | | 0 | 17 | | | 17 |
| | | 1 | 21 | | | 21 |
| | | 1 | 35 | | | 35 |
| | | 0 | 19 | | | 19 |
| | | 1 | 21 | | | 21 |
| | | 0 | 25 | | | 25 |
| | | 0 | 13 | | | 13 |
| | 0 | 8 | 393 | 0 | 0 | 393 |
| | 1 | 1 | 25 | | | 25 |
| | 2 | 2 | 14 | | | 14 |
| | 1 | 1 | 26 | | | 26 |
| | 3 | 3 | 17 | | | 17 |
| | 0 | 0 | 18 | | | 18 |
| | 1 | 1 | 13 | | | 13 |
| | 2 | 2 | 13 | | | 13 |
| | 1 | 1 | 24 | | | 24 |
| | 0 | 0 | 18 | | | 18 |
| | 0 | 0 | 17 | | | 17 |
| | 0 | 0 | 20 | | | 20 |
| | 0 | 0 | 11 | | | 11 |
| | 11 | 0 | 11 | 216 | 0 | 216 |
| | 0 | 0 | 0 | 20 | | 20 |
| | 0 | 0 | 0 | 12 | | 12 |
| | 0 | 49 | 49 | 24 | | 73 |
| | 1 | 156 | 157 | 28 | | 185 |
| | 0 | 14 | 14 | 13 | | 13 |
| | 0 | 11 | 11 | 18 | | 18 |
| | 0 | 14 | 14 | 15 | | 15 |
| | 0 | 10 | 10 | 10 | | 13 |
| | 1 | 6 | 7 | 22 | | 29 |
| | 1 | 3 | 4 | 18 | | 18 |
| | 0 | 4 | 4 | 20 | | 24 |
| | 0 | 6 | 6 | 3 | | 9 |
| | 3 | 273 | 276 | 206 | 0 | 482 |
| | 0 | 3 | 3 | 17 | | 17 |
| | 0 | 10 | 10 | 8 | | 18 |
| | 0 | 5 | 5 | 18 | | 18 |
| | 0 | 8 | 8 | 11 | | 11 |
| | 0 | 2 | 2 | 12 | | 12 |
| | 1 | 9 | 10 | 8 | | 18 |
| | 0 | 3 | 3 | 10 | | 10 |
| | 0 | 2 | 2 | 8 | | 8 |
| | 3 | 7 | | | | |

| 年度 | H20 | H21 | H22 | H23 | H24 | H25 |
|---------------------------------|-----|-----|-----|-----|-----|-----|
| インターフェ | | | | | | |
| 新規(B型) | 8 | 11 | 3 | 7 | 5 | 6 |
| 新規(C型) | 393 | 216 | 206 | 137 | 92 | 51 |
| 2回目制度利用 | 0 | 0 | 14 | 12 | 11 | 7 |
| 3剤併用療法(テラプレビル) | 0 | 0 | 0 | 5 | 43 | 11 |
| 3剤併用療法(シメプレビル) | 0 | 0 | 0 | 0 | 0 | 119 |
| 3剤併用療法(バニプレビノ) | 0 | 0 | 0 | 0 | 0 | 0 |
| 3剤併用療法(再治療) | | | | | | |
| IFN 計 | 401 | 227 | 223 | 161 | 151 | 194 |
| IFNフリー | | | | | | |
| 新規(ダクラタスビル+アスナプレト) | 0 | 0 | 0 | 0 | 0 | 0 |
| 新規(ソホスブビル+リバビリン) | 0 | 0 | 0 | 0 | 0 | 0 |
| 新規(レシバスビル+ソホスブビ) | 0 | 0 | 0 | 0 | 0 | 0 |
| 新規(オムビタスビル+パリタプレ) | 0 | 0 | 0 | 0 | 0 | 0 |
| 新規(オムビタスビル+パリタプレビル+リトナビル+リバビリン) | | | | | | |
| 新規(エルバスビル+グラゾプレビル) | | | | | | |
| 新規(ダクラタスビル+アスナプレビル+ヘクラブビル) | | | | | | |
| 新規(グレカプレビル+ヒブレンタスビル) | | | | | | |
| 再治療 | | | | | | |
| 小計 | 0 | 0 | 0 | 0 | 0 | 0 |
| 核酸アナロ | | | | | | |
| 新規 | 0 | 0 | 273 | 65 | 56 | 61 |
| 更新 | 0 | 0 | 0 | 244 | 301 | 324 |
| 小計 | 0 | 0 | 273 | 309 | 357 | 385 |
| 累 計 | 401 | 227 | 496 | 470 | 508 | 579 |

| 年度 | H20 | H21 | H22 | H23 | H24 | H25 |
|--------|-----|-----|-----|-----|------|------|
| 新規(C型) | | | | | | |
| IFN2剤 | 393 | 216 | 206 | 137 | 92 | 51 |
| IFN3剤 | 0 | 0 | 0 | 5 | 43 | 130 |
| IFNフリー | 0 | 0 | 0 | 0 | 0 | 0 |
| 累計 | | | | | | |
| IFN2剤 | 393 | 609 | 815 | 952 | 1044 | 1095 |
| IFN3剤 | 0 | 0 | 0 | 5 | 48 | 178 |
| IFNフリー | 0 | 0 | 0 | 0 | 0 | 0 |



| 年度 | H21 | H21 | H22 | H23 | H24 | H25 |
|--------|-----|-----|-----|-----|-----|-----|
| 新規(B型) | | | | | | |
| IFN2剤 | 8 | 11 | 3 | 7 | 5 | 6 |
| 核酸アナログ | 0 | 0 | 273 | 65 | 56 | 61 |
| 累計 | | | | | | |
| IFN2剤 | 8 | 19 | 22 | 29 | 34 | 40 |
| 核酸アナログ | 0 | 0 | 273 | 338 | 394 | 455 |

| H26 | H27 | H28 | H29 | H30 | H31 | H32 | 累計 |
|-----|------|-----|-----|-----|-----|-----|------|
| 7 | 4 | 0 | 0 | 0 | 0 | 0 | 51 |
| 39 | 6 | 0 | 0 | 0 | 0 | 0 | 1140 |
| 3 | 0 | 0 | 0 | 0 | 0 | 0 | 47 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 59 |
| 103 | 5 | 0 | 0 | 0 | 0 | 0 | 227 |
| 6 | 2 | 0 | 0 | 0 | 0 | 0 | 8 |
| | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 158 | 17 | 0 | 0 | 0 | 0 | 0 | 1532 |
| 125 | 107 | 6 | 0 | 0 | 0 | 0 | 238 |
| 0 | 183 | 105 | 57 | 0 | 0 | 0 | 345 |
| 0 | 410 | 201 | 69 | 0 | 0 | 0 | 680 |
| 0 | 10 | 12 | 5 | 0 | 0 | 0 | 27 |
| | | 1 | 1 | 0 | 0 | 0 | 2 |
| | | 17 | 18 | 0 | 0 | 0 | 35 |
| | | 0 | 0 | 0 | 0 | 0 | 0 |
| | | | 57 | 0 | 0 | 0 | 57 |
| | 0 | 1 | 9 | 0 | 0 | 0 | 10 |
| 125 | 710 | 343 | 216 | 0 | 0 | 0 | 1394 |
| 65 | 78 | 77 | 57 | 0 | 0 | 0 | 732 |
| 357 | 394 | 460 | 473 | 0 | 0 | 0 | 2553 |
| 422 | 472 | 537 | 530 | 0 | 0 | 0 | 3285 |
| 580 | 1199 | 880 | 746 | 0 | 0 | 0 | 6086 |

| H26 | H27 | H28 | H29 | H30 | H31 | H32 | 累計 |
|------|------|------|------|------|------|------|------|
| 39 | 6 | 0 | 0 | 0 | 0 | 0 | 1140 |
| 109 | 7 | 0 | 0 | 0 | 0 | 0 | 294 |
| 125 | 710 | 342 | 207 | 0 | 0 | 0 | 1384 |
| 1134 | 1140 | 1140 | 1140 | 1140 | 1140 | 1140 | |
| 287 | 294 | 294 | 294 | 294 | 294 | 294 | |
| 125 | 835 | 1177 | 1384 | 1384 | 1384 | 1384 | |

| H26 | H27 | H28 | H29 | H30 | H31 | H32 | 累計 |
|-----|-----|-----|-----|-----|-----|-----|-----|
| 7 | 4 | 0 | 0 | 0 | 0 | 0 | 51 |
| 65 | 78 | 77 | 57 | 0 | 0 | 0 | 675 |
| 47 | 51 | 51 | 51 | 51 | 51 | 51 | |
| 520 | 598 | 675 | 732 | 732 | 732 | 732 | |

高知県での肝炎治療費助成利用者数の薬剤種類別年度別推移(C型)



※IFNフリーの薬剤別利用者数

| 区分 | 商品名 | H26 | H27 | H28 | H29 | 計 |
|----|---------------|-----|-----|-----|-----|-------|
| 1型 | ダクルインザ・スンベブラ | 125 | 107 | 6 | 0 | 238 |
| | ハーボニー | 0 | 410 | 201 | 69 | 680 |
| | ヴィキラックス | 0 | 10 | 12 | 5 | 27 |
| | エレルサ・グラジナ | | | 17 | 18 | 35 |
| | ジメンシー | | | 0 | 0 | 0 |
| 2型 | ソバルディ・リバビリン | 0 | 183 | 105 | 57 | 345 |
| | ヴィキラックス・リバビリン | | | 1 | 1 | 2 |
| 全 | マヴィレット | | | | 57 | 57 |
| | 再治療 | | | 1 | 9 | 10 |
| | 計 | 125 | 710 | 343 | 216 | 1,394 |

高知県での肝炎治療費助成利用者数の薬剤種類別年度別推移(B型)

